These data suggest that the mutations identified most frequently in Ph+ ALL do not confer an intrinsic, clinically apparent proliferative advantage over leukemic cells expressing unmutated BCR-ABL. Most studies reporting the presence of pretherapeutic KD mutations in CML patients also found them to be...